isotretinoin

JDD June 2024 Issue Highlights
acneIn this June edition of the Journal of Drugs in Dermatology (JDD), we're excited to showcase a selection of groundbreaking research and expert insights that delve into the latest advancements and treatments in dermatology. From innovative acne scar therapies to in-depth analyses of topical acne treatments, this month's featured articles  provide a comprehensive overview of current dermatological …
acne
Refractory Dissecting Cellulitis of the Scalp Treated With Risankizumab
Dissecting CellulitisPerifolliculitis capitis abscedens et suffodiens or dissecting cellulitis (DC) is a rare and chronic disease with a predilection for the occipital, vertex, and parietal scalp. DC is characterized by multinodular lesions with purulent drainage and sinus tract formation. It is classically seen in middle-aged males of African descent. The etiology of the disease is unknown; however, leading theories …
Dissecting Cellulitis
Self-Reported Long-Term Side Effects of Isotretinoin: A Case Series
isotretinoin In this brief communication, JDD authors T. Roxana Ghadimi BS, Michael J. Martinez BS, and Evan A. Rieder MD present self-reported long-term, remote side effects to isotretinoin that dermatologists must be aware of. INTRODUCTION Isotretinoin is considered the gold standard treatment for severe nodulocystic acne, though it has been the subject of controversy in the media for concerns relate …
isotretinoin
Acne Vulgaris Treatment Update
acne vulgarisNext Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr. Hilary Baldwin, a board-certified dermatologist and medical director of the Acne Treatment & Research Center in Morristown, NJ and Brooklyn, NY. With the heavy acne tool box these days, how do you pick which medications to use? …
acne vulgaris
JDD April 2023 Issue Highlights
The April issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, features, and case reports,  with topics ranging from hormonal therapy in hidradenitis suppurativa, private equity in dermatology, vitiligo and its associated comorbidities, novel topical products for facial dyschromia, and many more.  Check out this month’s issue highlights straight …